Current clinicopathologic indicators are insufficient to distinguish the small percentage of aggressive prostate cancer (PCa) from the vast majority of indolent disease at diagnosis,leading to overtreatment of PCa.A recent study reported and confirmed a strong association of PCaspecific mortality with somatic DNA copy number alterations (CNAs) in primary prostate tumors.If a sensitive,robust and lowcost method can be developed to measure these CNAs in biopsy specimens,it may help to stratify patients for more appropriate management at the time of diagnosis;aggressive treatment or active surveillance for patients with or without these CNAs,respectively.